PENNSYLVANIA – The Janssen Pharmaceutical Companies of Johnson & Johnson announced positive topline results from its Phase 2b FRONTIER 1 clinical trial evaluating the novel, first and only oral interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 in adult patients with moderate-to-severe plaque psoriasis (PsO).1 The trial achieved all primary and secondary efficacy endpoints. A greater proportion of patients who received JNJ-2113 achieved …